BRANMOOR
THURSDAY · 14 MAY 2026

Docetaxel Anhydrous

Injection · trading as Docetaxel

To Be Discontinued Active (discontinuing) — Day 324 FDA record updated

High impact — Sole-source drug with no supply currently available from this manufacturer.

FDA shortage record

Substance
Docetaxel Anhydrous
Brand name
Docetaxel
Manufacturers / suppliers
  • Hospira, Inc.
  • Pfizer Inc.
2 known suppliers in current FDA data
Dosage form
Injection
Presentation
Docetaxel, Injection, 160 mg/16 mL (10 mg/mL) Multiple Dose ONCO-TAIN™ Glass Fliptop Vial Novaplus® (NDC 0409-0016-01)
Route(s)
INTRAVENOUS
Therapeutic category
Oncology
Package NDC
0409-0016-01
Initially posted
06/24/2025
Days on shortage list
324
Discontinued
06/24/2025
Current FDA status
To Be Discontinued
Shortage entries (current dataset)
1 record for Docetaxel Anhydrous

Why this shortage matters

Oncology drugs treat cancers including solid tumors, leukemia, and lymphoma. Shortages of chemotherapy agents can delay or interrupt regimens where dose timing and intensity directly affect treatment outcomes.

FDA therapeutic class: Oncology

Reason and context

Discontinuation of the manufacture of the drug

Manufacturer contact

Per the FDA record, the manufacturer's contact for supply inquiries is 844-646-4398.

If you're affected by this shortage

  • Talk to your prescribing clinician or pharmacist about therapeutic alternatives. Do not switch medications on your own.
  • Ask your pharmacy to check supply across multiple wholesalers and other branches.
  • Check current pharmacy pricing and availability via GoodRx (affiliate link).
  • Report a continuing supply problem to FDA via the FDA Drug Shortages contact form.

Sources

Important

This page reproduces publicly available FDA shortage data for informational purposes only. It is not medical advice and does not establish a clinician-patient relationship. Shortage status changes frequently; verify directly with your pharmacist or the FDA Drug Shortages site before making any treatment decision.